Hyperion DeFi, Inc.
$4.28
▼
-0.61%
2026-04-21 07:25:00
hyperiondefi.com
NCM: HYPD
Explore Hyperion DeFi, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$48.76 M
Current Price
$4.28
52W High / Low
$17.18 / $1.02
Stock P/E
—
Book Value
$4.73
Dividend Yield
—
ROCE
-38.69%
ROE
-3.24%
Face Value
—
EPS
$-9.4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
9
Beta
2.63
Debt / Equity
20.74
Current Ratio
2.68
Quick Ratio
2.68
Forward P/E
—
Price / Sales
50.83
Enterprise Value
$43.42 M
EV / EBITDA
-2.49
EV / Revenue
53.38
Rating
None
Target Price
$6.28
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Amicus Therapeutics, Inc. | $14.46 | — | $4.54 B | — | 4.84% | -11.58% | $14.48 / $5.51 | $0.88 |
| 2. | Dyne Therapeutics, Inc. | $20.02 | — | $3.37 B | — | -41.2% | -55.71% | $25 / $7.38 | $5.89 |
| 3. | Ocugen, Inc. | $1.85 | — | $606.61 M | — | -307.31% | -7.77% | $2.73 / $0.64 | $-0.04 |
| 4. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 5. | Instil Bio, Inc. | $8.39 | — | $56.9 M | — | -26.15% | -50.39% | $42.79 / $5.67 | $16.79 |
| 6. | Immatics N.V. | $11.25 | — | $1.51 B | — | -35.05% | -37.1% | $12.41 / $3.94 | $4.18 |
| 7. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.5 M | 0.3 M | 0 M | 0.01 M | 0.03 M | — |
| Operating Profit | -4.93 M | -2.67 M | -8.35 M | -3.03 M | -8.24 M | — |
| Net Profit | -39.77 M | 6.63 M | -8.69 M | -3.48 M | -19.95 M | — |
| EPS in Rs | -3.49 | 0.58 | -0.76 | -0.31 | -1.75 | -9.07 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.81 M | 0.06 M | 0 M | 0 M |
| Operating Profit | -18.98 M | -37.53 M | -25.41 M | -26.91 M |
| Net Profit | -45.31 M | -49.82 M | -27.26 M | -28.01 M |
| EPS in Rs | -3.98 | -4.37 | -2.39 | -2.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 51.76 M | 3.67 M | 28.78 M | 31.04 M |
| Total Liabilities | 10.7 M | 16.76 M | 19.78 M | 13.8 M |
| Equity | 41.06 M | -13.1 M | 9 M | 17.23 M |
| Current Assets | 7.25 M | 2.77 M | 20.71 M | 27.64 M |
| Current Liabilities | 2.7 M | 16.05 M | 9.53 M | 4.51 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -14.77 M | -30.12 M | -23.84 M | -25.11 M |
| Investing CF | -71.95 M | -0.16 M | -3.97 M | -0.87 M |
| Financing CF | 91.05 M | 17.55 M | 19.79 M | 21.51 M |
| Free CF | -86.72 M | -30.28 M | -27.81 M | -25.98 M |
| Capex | -71.95 M | -0.16 M | -3.97 M | -0.87 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 1414.02% | — | — | — |
| Earnings Growth % | -82.75% | 2.68% | — | — |
| Profit Margin % | -86888.57% | -719859.94% | — | — |
| Operating Margin % | -65456.83% | -670885.82% | — | — |
| Gross Margin % | -6749.5% | -322.63% | — | — |
| EBITDA Margin % | -80587.33% | -636547.06% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-02-03 | 1:0.0125 |